Correlation of HER2/TOP2A Gene Aberrations with RASSF1A/APC Gene Methylation Status in High-Risk Breast Cancer

Ayşe Feyda NURSAL,1 Öğuz ÇİLİNGİR,2 Onur EROĞLU,3 Beyhan DURAK ARAS,2 Evrim ÇİFTÇİ,4 Canan BAYDEMİR,5 Sevilhan ARTAN2

1Department of Medical Genetics, Hitit University Faculty of Medicine, Çorum-Turkey
2Department of Medical Genetics, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir-Turkey
3Department of Molecular Biology and Genetic, Bilecik Seyh Edebali University Faculty of Art&Science, Bilecik-Turkey
4Department of Molecular Pathology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir-Turkey
5Department of Biostatistics and Medical Informatics, Kocaeli University Faculty of Medicine, Kocaeli-Turkey

OBJECTIVE
Breast cancer (BC) is a heterogeneous malignancy and differs widely among different patients. The aim of this study was to investigate the relationship between the HER2/TOP2A gene aberrations and promoter methylation in RASSF1A/APC genes in patients with high-risk BC.

METHODS
Formalin-fixed paraffin embedded (FFPE) tissue samples from primary breast tumors (n=60) were assessed. HER2/TOP2A aberrations was evaluated using FISH method. DNA was extracted from FFPE tumor tissues, and Methylation-sensitive high resolution melting (MS-HRM) analysis were performed for RASSF1A/APC genes methylation status.

RESULTS
HER2 amplification and TOP2A aberration were observed in 15/60 (25%) and 18/60 (30%) cases, respectively. According to the statistical analysis, HER2 amplification was associated with higher tumor grade (p=0.001), PR status (p=0.025), and TOP2A aberrations (p=0.004). RASSF1A and APC methylation were 58/60 (96.6%) and 26/60 (43.3%), respectively. There was a significant correlation between APC methylation and TOP2A aberration. APC gene methylation was significantly more frequent in tumors with TOP2A aberration (p=0.026).

CONCLUSION
Our results suggested that APC gene promoter hypermethylation was associated with TOP2A gene aberrations in patients with high-risk BC. This may be significant for targeted individual therapy. Additionally, it was confirmed that there was significant association of TOP2A gene aberrations with the HER2 gene amplification seen in BC.

Keywords: APC; Breast cancer; HER2; TOP2A; MS-HRM; RASSF1A.
Introduction

Breast cancer (BC) is the most common cancer type that affects women in the world population. Approximately 1.3 million women are diagnosed with BC annually worldwide.[1] Clinicopathologic features, such as tumor size, lymph node (LN) status, hormone receptor status, and invasion, play important roles in prognosis. Similar to other types of cancers, BC tumorigenesis is characterized as a multi-step process in which each step is thought to correlate genetic and/or non-genetic factors.

Human epidermal growth factor receptor 2 (HER2; aka erbB2) and its relatives belong to the HER family of receptor tyrosine kinases. The HER2 protein is a transmembrane glycoprotein with a size of 185-kD and belongs to the HER family of growth factor receptors.[2] The HER2 protein is overexpressed and/or amplified approximately in 15-20% of the BC and has both prognostic and predictive implications.[3] Topoisomerase 2 alpha (TOP2A) gene encodes a DNA topoisomerase that controls topologic states of DNA at transcription and replication.[4] TOP2A gene is found on chromosome 17 q12–q21, adjacent to the HER2 gene, and its aberrations (amplification or deletion) have been shown usually in HER2-positive breast cancers.[5]

Epigenetic abnormalities in neoplastic cells, including hypermethylation and hypomethylation of DNA, modified patterns of histones, and remodeled chromatin arrangement, lead to the modified expression of numerous fundamental genes. A well-categorized epigenetic change is hypermethylation of tumor-suppressor promoters that result in improper transcription silencing of these genes.[6] The tumor suppressor gene RASSF-association domain family member 1 (RASSF1A) encodes a member of the group of RAS effectors that modulates cell proliferation, apoptosis, and microtubule stability. Hypermethylation of RASSF1A was detected in a significant percentage of several primary tumors.[7] Epigenetic silencing of the RASSF1A is assumed to be an early cancer biomarker, but this process is extended from primary to metastatic tumors during tumor progression.[8] The adenomatous polyposis coli (APC) gene, located in chromosome 5q21, plays an essential role in the pathogenesis of colorectal cancer, both in the autosomal dominant inherited familial APC syndrome and in sporadic colorectal cancer.[9] It has been proposed that the impairment of the APC/β-catenin pathway may play a role in BC. Lack of APC expression and upregulation of β-catenin have been identified in human BC and BC cells.[10]

Although BC therapy differs by subtype, there are standard treatments that are currently administered based on subtype. The oncogenic issues and signalling pathways that drive these tumor subtypes are definite, showing that a better comprehension of their molecular basis will render possibilities for predicting response to chemotherapy and implementing novel treatment modalities, to finally improve patient outcomes. Therefore, in this study, we aimed to investigate the relationship between HER2/TOP2A aberrations which in predictive markers in BC and methylation status of RASSF1A/APC genes in high-risk patients with BC.

Materials and Methods

Case Selection

In this study, formalin-fixed paraffin-embedded (FFPE) sections of tissue from 60 high-risk BC patients were obtained in the Department of Pathology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey. The inclusion criteria of samples were applied to include the BC patients with (1) tumor size ≥2 cm and/or (2) lymphatic metastases and/or distant metastases and/or (3) patients under 40 years. Clinical parameters, such as tumor grade, histopathological type, the status of estrogen receptor (ER) and progesterone receptor (PR), were obtained from patient’s case files. All patients in this series were treated using standard anthracycline-based adjuvant chemotherapy. Informed consent was obtained from the patients whose clinical data could be accessed. The use of FFPE samples for this research was approved by the clinical studies local Ethics Committee (Eskisehir Osmangazi University-Medical Research Ethics 2010/173). This study was conducted in accord with the Helsinki Declaration.

Fluorescence in Situ Hybridization (FISH) Analysis

Fluorescence in situ hybridization (FISH) analysis was performed on 4 μm thick sections of FFPE samples. Commercially available FISH assays of CEP17, HER2 and TOP2A were done according to the manufacturer’s protocols (Zytovision, Germany). The kit consisted of a mixture of spectrum green-labeled HER2, spectrum red labeled TOP2A gene and spectrum aqua labeled centromere 17 (CEP17) specific probes. The three-color FISH analysis was performed on the slides of the FFPE tissue samples located in two separate, distinct microscopic areas. The tumors sections, containing at least 85% pure tumor cells, were selected during the histopathological analyses of the lesions. In the evaluation of fluorescence spots specific to HER2/TOP2A/CEP17,
absolute and relative numbers (relative to chromosome 17 copy number) of the individual genes were scored in a hundred randomly selected nuclei per tumor using an Olympus bx61 fluorescence microscope (Olympus, Tokyo, Japan) and images were captured using image analysis system (applied imaging, Newcastle, UK). In each FISH experiment, known positive and negative controls were used. In the FISH assessments, HER2/CEP17, TOP2A/CEP17 ratios were calculated. HER2/CEP17 ratio of ≥2 and TOP2A/CEP17 ratio of ≥1.5 were defined as positive for HER2/TOP2A amplification. TOP2A was considered deleted when TOP2A/CEP17 ratio <0.8.[11]

Methylation-Sensitive High-Resolution Melting (MS-HRM) Analysis

After deparaffinization, genomic DNA was extracted using MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche) according to the manufacturer’s instructions. The quantity and purity of isolated DNA were evaluated by NanoDrop 1000 spectrophotometer (Thermo Scientific, DE, USA). Subsequently, genomic DNA modified using sodium bisulfite to deaminate selectively unmethylated cytosine residues to uracil, while 5-methyl cytosine residues were not modified. The bisulphite modification was performed using the “EpiTect® Bisulfite Kit” (Qiagen) according to the manufacturer’s recommendations.

To determine the promoter methylation status of RASSF1A and APC genes, we used a real-time polymerase chain reaction (PCR) approach followed by high resolution melting curve analysis (HRM). PCR and HRM analysis were consecutively performed on a LightCycler® 480 (Roche Applied Science, Laval, PQ, Canada). PCR was performed in a 19.5 μl reaction volume, and 10 μl of BSC DNA templates were added to each well which contained 10 μl LightCycler 480 High Resolution Melting (HRM) Master Mix® (Roche) and 2.5 μl MgCl2 and 3.0 μl of each primer. The primer sequences were based on the previous report [12] as follows: Methylated RASSF1A; F-5’-GTGTTAACCGGTTGCTATC-3’; R-5’-AACCCC-GCGAACTAAAAACGA-3’. RASSF1A unmethylated; F-5’-TTTGTGTTGGAGTGTTAATGTG-3’; R-5’-CAAACGCCCAAACAAAAACAA-3’APC methylated; F-5’-TATTGCGGAGTGCGGGTC-3’; R-5’-TCGACGAACTCCCGACGA-3’. APC unmethylated; F-5’-GTGTTTTATTGTTGAGTGTTGAGT-3’; R-5’-CCAATCACAAACTCCCAACAA-3’. The amplification consisted of 10 min at 95°C, followed by 50 cycles of 10 s at 95°C, 15 s at annealing temperature and 25 s at 72°C. Fluorescence data were collected at 25 acquisitions per second. The LC480-HRM Master Mix® employed a saturating dye (ResolLight™, Roche), which facilitated the precise measurement of the melt curves of the amplicons. The Roche Gene Scanning software was employed for end-product analysis. This algorithm allowed the raw melt curves to be normalized for fluorescence intensity, and a temperature shift was applied to align the normalized melt curves, which facilitated the analysis of samples with varying crossing point values. A difference curve was then derived from the first derivative of the melt curves. Data for the difference melt curves were transmitted to Excel (Office 2010; Microsoft Corp., Redmond, WA, USA). Both peak-height and area-under-the-curve from the normalized, temperature-shifted, difference curves were used to create a standard curve and determine the degree of methylation of each DNA sample.

Statistical Analysis

All statistical analyses were performed using IBM SPSS for Windows version 20.0 (SPSS, Chicago, IL, USA). Comparisons of categorical variables between the clinicopathological parameters, HER2/TOP2A aberrations and RASSF1A/APC methylation status were performed using the Fisher exact test and the Monte Carlo chi-square test. A two-sided p-value <0.05 was considered statistically significant. Overall survival was estimated with the Kaplan-Meier method (Log-rank Test).

Results

A total of 60 cases were included in this study. All cases were female. The median age of patients was 59.23±1.40 years (range 36 to 81 years). There was no statistical association between histopathological type, grade and ER/PR status. The baseline clinicopathological features of the tumor samples are presented in Table 1. The characteristics of tumor samples according to HER2 gene status are summarized in Table 2.

HER2/TOP2A aberrations

HER2 gene amplification was observed in 15/60 samples (25%). All samples with HER2 amplified had invasive ductal carcinoma. HER2 amplification was more frequent in higher-grade tumors (p=0.001) and PR negativity (p=0.025), and TOP2A aberrations (p=0.004) (Table 3). TOP2A aberration was found in 18/69 (30.0%) (6.6% deletion and 23.4% amplification). Although there was not any statistical difference, the majority of the patients with HER2 and TOP2A aberration were over the age of 45 years.
significant difference between RASSF1A/APC methylation status and histopathological type, grade and ER/PR status (p>0.05). There was a significant relationship between APC methylation and TOP2A aberration (p=0.026). APC gene methylation was significantly higher in patients with TOP2A aberration (p=0.026) (Table 3).

When RASSF1A gene methylation of 19 patients who are alive and under follow-up was examined, the findings showed that 18 tumor samples were methylated, and 1 sample was unmethylated. As APC gene methylation was assessed in 19 patients who were alive and under follow up, samples from 11 patients were unmethylated and samples from 8 patients were methylated. There was not any statistically significant result in life analysis carried out with RASSF1A and APC gene methylation.

Discussion

BC, a heterogeneous disease representing a wide range of pathological entities and clinical behaviors, is an important health problem in all over the world as well as in Turkey. In the present study, we investigated the correlation between HER2/TOP2A gene aberrations and RASSF1A/APC promoter methylation status in tumors with high-risk BC.

Human epidermal growth factor family consists of several receptors with tyrosine kinase activity which has an impact on cell proliferation and survival. The dimerization of HER family members results in the autophosphorylation of tyrosine residues in the cytoplasmic domain and induces cell proliferation and tumorigenesis.[13] While HER family members do not have a natural ligand for signalling, several synthetic ligands have been developed and they are shown to be effective in drug delivery. Of all-family members, HER2 is a crucial molecule and expression of HER2 is increased in several cancer types. HER2 amplification is among the most common genetic alterations in BC.[14] HER2 amplification is an adverse prognostic factor and a predictive biomarker of response to HER2-targeted treatment.[14] Furthermore, HER2 amplification is functionally proposed as a driver of genomic instability and thus may simultaneously cause amplification and activation of other genes.[15] Co-amplified genes found in the smallest region of amplification of HER2 amplicon include MED1, STARD3, GRB7, THRA, and RARA.[16] TOP2A, located in a separate amplicon downstream to HER2 amplicon, is often modified in HER2-amplified tumors.[16] Targeted inhibition of Topoisomerase II alpha enzyme at a molecular level ac-

| Table 1 | Baseline characteristics of BC patients |
|---------------------|---------------------|
| **Baseline characteristics** | n (%) |
| Age Mean | 59.23 (±1.40) |
| Histopathological Type |  |
| Invasive ductal carcinoma | 49 (81.6) |
| Invasive lobular carcinoma | 5 (8.3) |
| Other | 6 (10) |
| Grade |  |
| I | 6 (10) |
| II | 23 (38.4) |
| III | 13 (21.6) |
| Unknown | 18 (40.0) |
| ER status |  |
| Negative | 25 (41.6) |
| Positive | 35 (58.4) |
| PR status |  |
| Negative | 29 (48.3) |
| Positive | 31 (51.7) |
| HER2 Normal | 45 (75) |
| Amplified | 15 (25) |
| TOP2A Deleted | 4 (6.6) |
| Normal | 42 (70) |
| Amplified | 14 (23.4) |
| RASSF1A Unmethylated | 2 (3.4) |
| Methylated | 58 (96.6) |
| APC Unmethylated | 34 (56.7) |
| Methylated | 26 (43.3) |

When the HER2 gene status was evaluated in 19 patients who were alive and under follow-up, 17 patients with normal gene copy number were found to have a 0.82 probability of survival at the 4th year of life and 2 cases with HER2 gene amplification had 0.50 probability of survival at the 4th year of life. The difference was not statistically significant (Log-rank=0.139, p=0.399). When the TOP2A gene status was assessed in 19 patients who were alive and under follow-up, 15 patients with normal TOP2A gene had a 0.80 probability of survival in the 3rd year and four patients with TOP2A gene amplification had 0.25 probability of survival in the 3rd year. There was no statistically significant difference (Log-rank=0.710 p=0.399).

RASSF1A/APC methylation

RASSF1A and APC promoter methylation were observed in 58/60 samples (96.6%) and 26/60 (43.3%), respectively. The findings showed that there was no
counts for the cytotoxic effect of the TOP2A inhibitors, such as the anthracycline class.

In the present study, the findings showed that HER2 gene amplification was 25% and TOP2A gene aberrations were 30% (6.6% deletion and 23.4% amplification). Several studies have also reported that TOP2A aberrations are rare in patients with normal HER2.[17] It was reported that TOP2A aberration was present in 50-80% of the patients with HER2 amplification.[18] In the present study, TOP2A aberrations occurred in 17.7% of HER2 non-amplified cases (13.3% deletion and 4.4% amplification), while TOP2A aberration was present in 66.6% (13.3% deletion and 53.3% amplification) of HER2 amplified cases (p=0.004). These results support many previous studies reporting a close relationship between HER2 and TOP2A genes, whereas HER2/TOP2A co-amplification was reported as 35% by Press et al.,[19] as 39% by Bhargava et al.,[20] in the present study, HER2/TOP2A co-amplification was found in 13.3% of the patients. This result may be due to the diversity in methodology and/or established cut-off values. Moreover, although being statistically insignificant, we found that HER2 and TOP2A co-amplification was more common in patients with advanced age.

Epigenetic events are crucial factors in the pathogenesis of human cancers. Aberrant methylation in the promoter regions of tumor suppressor genes is associated with carcinogenesis via transcriptional silencing of gene expression, resulting in the onset and development of cancer.[21] RASSF1A promoter methylation provides significant prognostic information in early-

### Table 2  Characteristics of tumor samples according to HER2 gene status

| HER2 gene | Normal n (%) | Amplification n (%) | χ² | p   |
|-----------|--------------|---------------------|----|-----|
|           | Histopathological Type |               |    |     |
|           | Invasive ductal | 34 (75.6) | 15 (100.0) | 4.490 | 0.095 |
|           | Invasive lobular | 5 (11.1) | 0 (0.0) |     |     |
|           | Other | 6 (13.3) | 0 (0.0) |     |     |
| Grade |              |               |    |     |
| Known | 16 (35.6) | 2 (13.3) | 18.126 | 0.001 |
| I | 6 (13.3) | 0 (0.0) |     |     |
| II | 19 (42.2) | 4 (26.7) |     |     |
| III | 4 (8.9) | 9 (60.0) |     |     |
| ER |              |               |    |     |
| ER (−) | 16 (35.6) | 9 (60) | 2.766 | 0.096 |
| ER (+) | 29 (64.4) | 6 (60) |     |     |
| PR |              |               |    |     |
| PR (−) | 18 (40) | 11 (73.3) | 5.006 | 0.025 |
| PR (+) | 27 (60) | 4 (26.7) |     |     |
| TOP2A |              |               |    |     |
| Normal | 37 (82.3) | 5 (33.3) | 12.889 | 0.004 |
| Amplification | 6 (13.3) | 8 (53.4) |     |     |
| Deletion | 2 (4.4) | 2 (13.3) |     |     |
| RASSF1A |              |               |    |     |
| Unmethylated | 2 (4) | 0 (0) | 2.415 | 0.811 |
| Methylated | 43 (96) | 15 (100) |     |     |
| APC |              |               |    |     |
| Unmethylated | 19 (42.1) | 8 (53.4) | 6.373 | 0.172 |
| Methylated | 26 (57.9) | 7 (46.6) |     |     |

### Table 3  TOP2A gene aberrations according to APC gene methylation

| APC gene | Methylated n (%) | Unmethylated n (%) | χ² | p   |
|-----------|------------------|--------------------|----|-----|
| TOP2A |               |                   |    |     |
| Normal | 15 (36) | 27 (64.0) | 21.335 | 0.026 |
| Amplification | 9 (64) | 5 (36.0) |     |     |
| Deletion | 2 (50.0) | 2 (50.0) |     |     |
Our results suggested that APC gene promoter hypermethylated was associated with TOP2A gene aberrations. These results suggest that TOP2A aberrations contribute to the epigenetic mechanisms in BC. Our data can provide a new option for individualized treatment. Additionally, in this study, it was confirmed that there was a significant relationship between HER2 amplification and TOP2A gene aberration.

**Acknowledgement:** This study was presented at the 4th International Health Science and Family Medicine Congress, 2019.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.

**Ethics Committee Approval:** The study has been approved by the Medical research Ethics Committee of the Medical Faculty of Eskisehir Osmangazi University.

**Financial Support:** This study was supported by the Eskisehir Osmangazi University Scientific Research Foundation, Project number: 201011037.

**Authorship contributions:** Concept – A.F.N., O.Ç., S.A.; Design – S.A., B.D.A., A.F.N.; Supervision – S.A., O.Ç., B.D.A.; Materials – E.Ç., O.E.; Data collection &/or processing – A.F.N., O.E., O.Ç.; Analysis and/or interpretation – A.F.N., O.E., B.D.A.; Literature search – S.A., C.B., A.F.N.; Writing – A.F.N., O.Ç., C.B.; Critical review – S.A., O.Ç., E.Ç.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebello M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86.

2. Canda T, Yavuz E, Ozdemir N, Ilvan S, Dizbay SS, Durak MG, et al. Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. Eur J Breast Health 2018;14(3):160–5.

3. Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, et al. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019;118:1–9.

4. Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, et al.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 2012;10:10.

5. Eltohamy MI, Badawy OM, El kinaai N, Loay I, Nassar HR, Allam RM, et al. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients). Asian Pac J Cancer Prev 2018;19(12):3581–9.

6. Akar RO, Selvi S, Ulukaya E, Aztopal N. Key actors in cancer therapy: epigenetic modifiers. Turk J Biol 2019;43(3):155–70.
7. Vu TL, Nguyen TT, Doan VTH, Vo LTT. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer Asian Pac J Cancer Prev 2018;19:1887–93.

8. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliaabue E, Xu J, et al. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 2010;10:378.

9. Wang B, Song H, Jiang H, Fu Y, Ding X, Zhou C. Early diagnostic potential of APC hypermethylation in esophageal cancer. Cancer Manag Res 2018;10:181–98.

10. Jönsson M, Borg A, Nilbert M, Andersson T. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer 2000;36(2):242–8.

11. Beser AR, Tuzlali S, Guzey D, Dolek Guler S, Hacihanefioglu S, et al. HER-2, TOP2A and Chromosome 17 Alterations in Breast Cancer. Pathol Oncol Res 2007;13(3):180–5.

12. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, et al. Estrogen receptor and Her2/neu status effect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008;10(3):R46.

13. Nami B, Maadi H, Wang Z. The Effects of Pertuzumab and Its Combination with Trastuzumab on Homodimerization and Phosphorylation. Cancers (Basel) 2019;11(3): pii: E375.

14. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):3997–13.

15. Chen JR, Chien HP, Chen KS, Hwang CC, Chen HY, Yeh KY, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer. Medicine (Baltimore) 2017;96(2):e5582.

16. Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, et al. Aberrations of ERBB2 and TOP2A genes in a series of Taiwanese breast cancer. Medicine (Baltimore) 2017;96(2):e5582.

17. Slamon DJ, Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Tsiambas E, Fotiades PP, Sioka C, Ragos V. HER2/Topoisomerase IIa amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123(6):889–95.

18. Tsiambas E, Fotiades PP, Sioka C, Ragos V, Slamon DJ, Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Tsiambas E, Fotiades PP, Sioka C, Ragos V. HER2/Topoisomerase IIa amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123(6):889–95.

19. Beltrán-Garcia J, Osca-Verdugal R, Mena-Molla S, Garcia-Giménez JL. Epigenetic IVD Tests for Personalized Precision Medicine in Cancer. Front Genet 2019;10:621.

20. Yadav P, Masroor M, Nandi K, Kaza RCM, Jain SK, Khurana N, et al. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer. Asian Pac J Cancer Prev 2018;19(2):443–8.

21. Spitzwieser M, Holzweber E, Pfeifer G, Hacker S, Cichna-Markl M. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res 2015;17:125.

22. Jezkova E, Zubor P, Kajo K, Gendrar M, Dokus M, Adamkov M, et al. Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients. Oncol Lett 2017;14(1):758–66.

23. Liang Tj, Wang HX, Zheng YY, Cao YQ, Wu X, Zhou X, et al. APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review. Oncotarget 2017;8(28):46468–79.

24. Li BQ, Liu PP, Zhang CH. Correlation between the methylation of APC gene promoter and colon cancer. Oncol Lett 2017;14(2):2315–9.

25. He K, Zhang L, Long X. Quantitative assessment of the association between APC promoter methylation and breast cancer. Oncotarget 2016;7(25):37920–30.

26. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001;85(1):69–73.

27. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005;11(6):2156–62.

28. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011;458(1):73–84.

29. Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcano KF. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer patients and benign breast disease controls. Epigenetics 2012;7(11):1258–67.

30. Zhou D, Tang W, Wang W, Pan X, An HX, Zhang Y. Association between aberrant APC promoter methylation and breast cancer pathogenesis: a meta-analysis of 35 observational studies. PeerJ 2016;4:e2203.

31. Debouki-Joudi S, Trifa F, Khabir A, Sellami-Boudawara T, Frika M, Daoud J, et al. CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients. Cancer Biomark 2017;18(2):133–41.